How interferon affects breast cancer treatment outcomes
Regulation of Type I Interferon Pro-tumor Effects in Breast Cancer
This study is looking at how a substance called interferon can both help and hurt breast cancer treatment, with the goal of finding better ways to use it so that patients can respond more positively to therapies like chemotherapy and radiation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10672200 on NIH RePORTER |
What this research studies
This research investigates the complex role of interferon in breast cancer treatment, particularly how it can both promote and inhibit tumor growth. The study focuses on understanding the mechanisms behind interferon-stimulated genes that contribute to cancer cells' resistance to therapies like chemotherapy and radiotherapy. By exploring ways to inhibit the pro-tumor effects of interferon while preserving its anti-tumor benefits, the research aims to improve treatment responses for breast cancer patients. The approach involves detailed analysis of specific genes and proteins that influence cancer cell behavior in response to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients undergoing or considering adjuvant therapies like chemotherapy or radiotherapy.
Not a fit: Patients with non-breast cancers or those not receiving standard adjuvant therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective breast cancer treatments that overcome resistance and improve patient outcomes.
How similar studies have performed: Other research has shown promising results in targeting interferon pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Wu, Mei-Yi — University of Maryland Baltimore
- Study coordinator: Wu, Mei-Yi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.